Top

Published in:

01-12-2007 | Scientific Article

A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid

Authors: Carlo C. Quattrocchi, Daniele Santini, Paola Dell’Aia, Sara Piciucchi, Emanuele Leoncini, Bruno Vincenzi, Rosario Francesco Grasso, Giuseppe Tonini, Bruno Beomonte Zobel

Published in: Skeletal Radiology | Issue 12/2007

Abstract

Objective

The objective was to prospectively determine CT density changes in bone metastases, before and after intravenous zoledronic acid for a maximum period of 12 months.

Patients and methods

Twenty-three consecutive patients presented with bone metastases and underwent therapy with zoledronic acid from December 2004. All patients underwent CT of the chest, abdomen, and pelvis. Bone density, measured in Hounsfield units (HU), was determined by segmenting lesions in the same anatomical area of the metastasis sites on the axial images of the sequential series of CT examinations. The effects of zoledronic acid were evaluated by calculating absolute and relative increases in bone density.

Results

The patients presented with multiple metastases in 65% of the cases. When compared with the baseline, all groups demonstrated a significant increase in bone density, which significantly (p < 0.01) correlated with the number of zoledronic acid administrations. There was increased bone density of at least 100% in 57%, and an increase of at least 50% in 87% of the patients. This increase was significant in both lytic and sclerotic metastases after 3 months of therapy. No significant bone density difference was found in normal-appearing bone.

Conclusion

Bone density measured by CT increases at metastatic sites after zoledronic acid treatment, regardless of the type of metastasis, in contrast to apparently normal bone.

Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22(14): 2942–2953.PubMedCrossRef

Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292–298.PubMed

Mundy GR. Mechanisms of bone metastasis. Cancer 1997; 80(8 Suppl): 1546–1556.PubMedCrossRef

Shih LY, Shih HN, Chen TH. Bone resorption activity of osteolytic metastatic lung and breast cancers. J Orthop Res 2004; 22(6): 1161–1167.PubMedCrossRef

Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10(2): 169–180.PubMedCrossRef

Kido DK, Gould R, Taati F, Duncan A, Schnur J. Comparative sensitivity of CT scans, radiographs and radionuclide bone scans in detecting metastatic calvarial lesions. Radiology 1978; 128(2): 371–375.PubMed

O’Connor SD, Yao J, Summers RM. Lytic metastases in thoracolumbar spine: computer-aided detection at CT—preliminary study. Radiology 2007; 242(3): 811–816.PubMed

Body JJ. Clinical trials in metastatic breast cancer to bone: past–present–future. Can J Oncol 1995; 5(1): 16–27.PubMed

Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785–1791.PubMedCrossRef

10.

Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–493.PubMedCrossRef

11.

Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994; 70: 554–558.PubMed

12.

Paterson AHG, Powles TJ, Kanis JA, et al. Double blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59–65.PubMed

13.

Lahtinen R, Laakso M, Palva I, et al. for the Finnish Leukaemia Group. Randomised, placebo-controlled multicenter trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049.PubMedCrossRef

14.

Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 2005; 96(7): 964–969.PubMedCrossRef

15.

Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97(1): 59–69.PubMedCrossRef

16.

Luckman SP, Hughes DE, Coxon FP. Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 1998; 13: 581–589.PubMedCrossRef

17.

Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E, Leotsinides M, Kardamakis D. Combination of ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 2007; 67(1): 264–272.PubMed

18.

Fromiguè O, Kheddoumi N, Body JJ. Bisphosphonates antagonize bone growth factors effects on human breast cancer cells survival. Br J Cancer 2003; 89: 178–184.PubMedCrossRef

19.

Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377–387.PubMed

20.

Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treatment Rev 1996; 22: 265–287.CrossRef

21.

Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003; 9(7): 2394–2399.PubMed

22.

Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer 2003; 98: 1735–1744.PubMedCrossRef

23.

Body JJ. Zoledronic acid: an advance in tumour bone disease and a new hope for osteoporosis. Expert Opin Pharmacother 2003; 4: 567–580.PubMedCrossRef

24.

Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23: 3314–3321.PubMedCrossRef

25.

Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer 2000; 88(12 Suppl): 3033–3037.PubMedCrossRef

26.

Huber S, Ulsperger E, Gomar C, Koderhold G, Czembirek H. Osseous metastases in breast cancer: radiographic monitoring of therapeutic response. Anticancer Res 2002; 22(2B): 1279–1288.PubMed

27.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.PubMedCrossRef

28.

Reinbold WD, Wannenmacher M, Hodapp N, Adler CP. Osteodensitometry of vertebral metastases after radiotherapy using quantitative computed tomography. Skeletal Radiol 1989; 18(7): 517–521.PubMedCrossRef

29.

Chow E, Holden L, Rubenstein J, et al. CT evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy: a feasibility study. Radiother Oncol 2004; 70(3): 291–294.PubMedCrossRef

30.

Quattrocchi CC, Piciucchi S, Sammarra M, et al. Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol Med 2007, in press.

31.

Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68(1): 74–80.PubMedCrossRef

32.

Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82(4): 858–864.PubMedCrossRef

33.

Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002; 62(3): 917–923.PubMed

34.

Roodman GD. Mechanisms of bone metastases. N Engl J Med 2004; 351(2): 195–196.CrossRef

35.

Martini G, Gozzetti A, Gennari L, Avanzati A, Nuti R, Lauria F. The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. Haematologica 2006; 91(12): 1720–1721.PubMed

36.

Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004; 19(1): 147–154.PubMedCrossRef

37.

Shapiro CL, Keating J, Angell JE, Janicek M, Gelman R, Hayes D, LeBoff MS. Monitoring therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: a prospective feasibility study in breast cancer patients. Cancer Invest 1999; 17(8): 566–574.

Title: A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid
Authors: Carlo C. Quattrocchi
Daniele Santini
Paola Dell’Aia
Sara Piciucchi
Emanuele Leoncini
Bruno Vincenzi
Rosario Francesco Grasso
Giuseppe Tonini
Bruno Beomonte Zobel
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Skeletal Radiology / Issue 12/2007
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI: https://doi.org/10.1007/s00256-007-0388-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid

Abstract

Objective

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2007

Soft tissue mass of the thigh: diagnosis and discussion

Bone graft substitutes

Four-dimensional computed tomographic imaging in the wrist: proof of feasibility in a cadaveric model

Three-dimensional spin-lock magnetic resonance imaging of the shoulder joint at 3 T: initial experience

MR imaging findings of anterior interosseous nerve lesions

Are radiographs needed when MR imaging is performed for non-acute knee symptoms in patients younger than 45 years of age?